Stoke Therapeutics (STOK) Liabilities and Shareholders Equity (2018 - 2026)

Stoke Therapeutics has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $443.3 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 8.94% year-over-year to $443.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (up 25.55% YoY), and the FY2025 full-year result was $418.4 million, up 54.09% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $443.3 million, up from $418.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $443.3 million in Q1 2026, with the low at $205.2 million in Q1 2024.
• Average Liabilities and Shareholders Equity over 5 years is $308.8 million, with a median of $293.3 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity dropped 27.19% in 2024 and soared 98.31% in 2025.
• Tracing STOK's Liabilities and Shareholders Equity over 5 years: stood at $256.1 million in 2022, then fell by 10.83% to $228.3 million in 2023, then gained by 18.92% to $271.6 million in 2024, then soared by 54.09% to $418.4 million in 2025, then rose by 5.94% to $443.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $443.3 million (Q1 2026), $418.4 million (Q4 2025), and $360.3 million (Q3 2025), per Business Quant data.

Peer Comparison